Cargando…

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi

Isavuconazole, the active moiety of the water-soluble prodrug isavuconazonium sulfate, is a triazole antifungal agent for the treatment of invasive fungal infections. The purpose of this analysis was to characterize the isavuconazole exposure-response relationship for measures of efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales:	Desai, Amit V., Kovanda, Laura L., Hope, William W., Andes, David, Mouton, Johan W., Kowalski, Donna L., Townsend, Robert W., Mujais, Salim, Bonate, Peter L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2017
Materias:	Clinical Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700339/ https://www.ncbi.nlm.nih.gov/pubmed/28923872 http://dx.doi.org/10.1128/AAC.01034-17

Ejemplares similares

Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi
por: Desai, Amit, et al.
Publicado: (2016)

Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics
por: Townsend, Robert W., et al.
Publicado: (2017)

Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
por: Kovanda, Laura L., et al.
Publicado: (2016)

Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
por: Desai, Amit, et al.
Publicado: (2016)

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials
por: Andes, David R., et al.
Publicado: (2018)

Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole
por: Kovanda, Laura L., et al.
Publicado: (2017)

2535. Physiological-based pharmacokinetic analysis of drug–drug interactions between isavuconazole and vincristine in pediatric subjects
por: Choules, Mary P, et al.
Publicado: (2023)

QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization
por: Keirns, J, et al.
Publicado: (2017)

Pharmacokinetic Interaction Between Isavuconazole and a Fixed‐Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects
por: Yamazaki, Takao, et al.
Publicado: (2016)

Pharmacokinetics and Bioequivalence of Isavuconazole Administered as Isavuconazonium Sulfate Intravenous Solution via Nasogastric Tube or Orally in Healthy Subjects
por: Desai, Amit, et al.
Publicado: (2021)

No Dose Adjustment for Isavuconazole Based on Age or Sex
por: Desai, Amit V., et al.
Publicado: (2019)

2537. Population Pharmacokinetics of Isavuconazole in Pediatric Patients
por: Desai, Amit, et al.
Publicado: (2023)

Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response
por: Kovanda, Laura L., et al.
Publicado: (2017)

Pharmacokinetic and Pharmacodynamic Evaluation of the Drug‐Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects
por: Desai, Amit, et al.
Publicado: (2016)

Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections
por: Donnelley, Monica A, et al.
Publicado: (2016)

Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats
por: Schmitt-Hoffmann, Anne-Hortense, et al.
Publicado: (2017)

Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis
por: Kovanda, Laura L., et al.
Publicado: (2019)

Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis
por: Kovanda, Laura L., et al.
Publicado: (2021)

Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects
por: Yamazaki, Takao, et al.
Publicado: (2016)

Filamentous Fungi in Respiratory Infections. What Lies Beyond Aspergillosis and Mucormycosis?
por: Chowdhary, Anuradha, et al.
Publicado: (2016)

Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects
por: Yamazaki, Takao, et al.
Publicado: (2016)

1396. Predictions of Isavuconazonium Sulfate Dosage in Patients Aged 6 Months: <18 Years by Physiologically Based Pharmacokinetic Modeling
por: Desai, Amit, et al.
Publicado: (2018)

Pharmacokinetic Assessment of Drug‐Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults
por: Groll, Andreas H., et al.
Publicado: (2016)

Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy
por: Jenks, Jeffrey D, et al.
Publicado: (2018)

Successful Treatment of Allergic Bronchopulmonary Aspergillosis With Isavuconazole: Case Report and Review of the Literature
por: Jacobs, Samantha E., et al.
Publicado: (2017)

Pharmacokinetic Evaluation of CYP3A4‐Mediated Drug‐Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults
por: Townsend, Robert, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
por: Harrington, Rachel, et al.
Publicado: (2016)

Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations
por: Natesan, Suganthini Krishnan, et al.
Publicado: (2016)

APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2019)

Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden
por: Floros, Lefteris, et al.
Publicado: (2019)

Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia
por: Miesel, Lynn, et al.
Publicado: (2021)

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses
por: Thompson, George R., et al.
Publicado: (2016)

Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2019)

Issues in the management of invasive pulmonary aspergillosis in non-neutropenic patients in the intensive care unit: A role for isavuconazole
por: Bassetti, Matteo, et al.
Publicado: (2018)

358. Comparison of Voriconazole (VORI), Isavuconazole (ISAV), and Posaconazole (POSA) in the Initial Treatment of Patients With Invasive Aspergillosis (IA)
por: Cheng, Matthew P, et al.
Publicado: (2018)

Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial
por: Perfect, John R., et al.
Publicado: (2018)

Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease
por: Lee, Annie, et al.
Publicado: (2019)

Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support
por: Miller, Michelle, et al.
Publicado: (2022)

Successful Multimodal Therapy with Intracerebral Liposomal Amphotericin B and Systemic High-Dose Isavuconazole in Proven Disseminated Aspergillosis
por: Feys, Simon, et al.
Publicado: (2023)

Exposure–Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials
por: Kovanda, Laura L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_35p6pjoa75svrsm4ts418nj70k